Feed aggregator

FDA approves first gene therapies to treat patients with sickle cell disease

World Pharma News - Fri, 12/08/2023 - 19:00
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy.

Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun

Biospace news - Fri, 12/08/2023 - 02:00
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun 12/8/2023

Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun

Biospace news - Fri, 12/08/2023 - 02:00
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun 12/8/2023

FDA Approves Two Gene Therapies for Sickle Cell, First CRISPR-Based Medicine

Biospace news - Fri, 12/08/2023 - 02:00
FDA Approves Two Gene Therapies for Sickle Cell, First CRISPR-Based Medicine 12/8/2023

Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study

Biospace news - Fri, 12/08/2023 - 02:00
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study 12/8/2023

Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal

Biospace news - Fri, 12/08/2023 - 02:00
Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal 12/8/2023

Rebranded Spyre Therapeutics Secures $180M to Advance IBD Antibody Pipeline

Biospace news - Fri, 12/08/2023 - 02:00
Rebranded Spyre Therapeutics Secures $180M to Advance IBD Antibody Pipeline 12/8/2023

Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case

Biospace news - Fri, 12/08/2023 - 02:00
Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case 12/8/2023

Axcella Health Becomes the Latest Flagship Company to Close its Doors

Biospace news - Fri, 12/08/2023 - 02:00
Axcella Health Becomes the Latest Flagship Company to Close its Doors 12/8/2023

Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook

Biospace news - Fri, 12/08/2023 - 02:00
Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook 12/8/2023

BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer

Biospace news - Fri, 12/08/2023 - 02:00
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer 12/8/2023

Bayer and Salus Optima partner on AI-enabled healthy aging journey

World Pharma News - Thu, 12/07/2023 - 11:00
Salus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.